Related Experiment Video

Updated: Apr 20, 2026

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression
06:29

Microfluidic Co-culture of Renal Healthy and Tumor Epithelium to Model Kidney Cancer Progression

Published on: January 31, 2025

1.4K

The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy

Katarzyna Kaminska1, Cezary Szczylik, Fei Lian

  • 1Department of Oncology with Laboratory of Molecular Oncology, Military Institute of Medicine, Szaserow 128, 04-141 Warsaw, Poland.

Future Oncology (London, England)
|December 5, 2014
PubMed

Insights

Targeting prostaglandin E2 (PGE2), a product of COX-2, shows promise in treating renal cell cancer (RCC). Inhibiting PGE2 may enhance current therapies and offer new treatment options for RCC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cyclooxygenase-2 (COX-2) is implicated in renal cell cancer (RCC) pathogenesis.
  • COX-2 inhibition improves outcomes with immunotherapy and tyrosine kinase inhibitors in RCC.
  • Prostaglandin E2 (PGE2), a COX-2 product, is increasingly recognized for its role in RCC development.

Purpose of the Study:

  • To investigate the role of prostaglandin E2 (PGE2) in renal cell cancer (RCC) development.
  • To explore the potential of targeting PGE2 as a therapeutic strategy for RCC.

Main Methods:

  • Molecular analyses of RCC cells.
  • Investigation of signaling pathways activated by PGE2, including Akt/RGC2/RalA and HIF-1α.
  • Assessment of the PI3K/Akt/mTOR signaling pathway in relation to PGE2 activity.

Main Results:

  • PGE2 activates the Akt/RGC2/RalA signaling cascade in RCC cells.
  • PGE2 upregulates the expression of HIF-1α.
  • PGE2 influences the PI3K/Akt/mTOR signaling pathway, suggesting a key role in RCC progression.

Conclusions:

  • Targeted anti-PGE2 therapies represent a potential future therapeutic avenue for renal cell cancer (RCC) patients.
  • Understanding PGE2's molecular mechanisms in RCC can guide the development of novel treatment strategies.
  • PGE2 inhibition may synergize with existing RCC treatments like immunotherapy and tyrosine kinase inhibitors.
Keywords:
COX-2NSAIDPGE-2celecoxibcyclooxygenase-2interferonprostaglandinrenal cell carcinomasunitinib

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy

Published on: April 29, 2014

17.4K
Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

934

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
626
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
5.0K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
4.0K